PET药物:2023年产品质量、监管申报、设施检查与获益-风险评估研讨会纪要
美国FDA于2023年11月13-14日在马里兰州银泉市FDA园区举办PET药物公开研讨会,由核医学与分子影像学会、医学影像与技术联盟及PET药物制造商联盟共同协办。会议围绕PET药品cGMP法规(21 CFR第212部分)与 investigational PET drugs(21 CFR第312部分)的合规与沟通展开,旨在澄清监管要求并改善PET药物生产指南的依从性。
要点
- FDA于2023年11月13-14日举办PET药物研讨会,聚焦产品质量、监管申报、设施检查与获益-风险。
- 会议旨在支持FDA与PET利益相关方持续沟通,澄清21 CFR第212部分cGMP法规及PET药物cGMP指南文件。
- 研讨会亦讨论了21 CFR第312部分下的研究性PET药物,因其与审批流程及最终cGMP生产法规密切相关。
核心结论
- 研讨会旨在支持FDA与PET利益相关方持续沟通,以澄清21 CFR第212部分PET cGMP法规及PET药物cGMP指南文件,目标是改善PET药物生产指南的依从性。
- 研究性PET药物(21 CFR第312部分)被讨论,因其与审批流程及最终进入临床使用后的cGMP生产法规密切相关。
研究设计与样本
- FDA主办的公开研讨会,由核医学与分子影像学会、医学影像与技术联盟及PET药物制造商联盟共同协办。
- 研讨会于2023年11月13-14日在马里兰州银泉市FDA园区举行。
- 会议针对2020年研讨会暴露的知识缺口及PET药物制造商调查反馈的主题展开讨论。
主要发现
- 2023年研讨会 addressing 了2020年研讨会期间出现的知识缺口以及PET药物制造商调查反馈中的主题。
- 本文总结了该研讨会上传达的讨论内容。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advances in PET radiopharmaceutical technologies necessitate continued dialogue between members of the PET drug manufacturing community and the U.S. Food and Drug Administration (FDA) to ensure that these drugs continue to be safe and effective and are sustainably supplied in accordance with regulatory commitments and current good manufacturing practice (cGMP) regulations. After the success of the 2020 PET drugs workshop, the FDA hosted a follow-up public workshop entitled "PET: Product Quality, Regulatory Submissions, Facility Inspections, and Benefit-Risk Considerations." The 2023 workshop addressed knowledge gaps that emerged during the 2020 workshop and themes from responses to a survey of PET drug manufacturers. The goal of this workshop was to support continued communication between the FDA and PET stakeholders to drive clarity toward PET cGMP regulations described in the Code of Federal Regulations (title 21, part 212) and PET Drug cGMP guidance documents, with the objective to improve compliance with PET drug manufacturing guidelines. In addition, investigational PET drugs (Code of Federal Regulations, title 21, part 312) were discussed, as they are intimately connected with the approval process and eventual cGMP manufacturing regulations once they matriculate to clinical use. The workshop was held on November 13-14, 2023, on the FDA campus in Silver Spring, MD. The Society of Nuclear Medicine and Molecular Imaging, the Medical Imaging and Technology Alliance, and the Coalition of PET Drug Manufacturers cosponsored the workshop with the FDA. This article summarizes the discussions that were conveyed at this workshop.
引用
- Bunning S, Christodoulou D, Cohen JE, et al. Proceedings: PET Drugs-A 2023 Workshop on Product Quality, Regulatory Submissions, Facility Inspections, and Benefit-Risk Considerations. J Nucl Med. 2025. PMID: 40707140. doi:10.2967/jnumed.125.270011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。